Department of Biology, Faculty of Sciences, Autónoma University of Madrid (UAM), Madrid 28049, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain.
Department of Biology, Faculty of Sciences, Autónoma University of Madrid (UAM), Madrid 28049, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain.
J Photochem Photobiol B. 2022 Aug;233:112483. doi: 10.1016/j.jphotobiol.2022.112483. Epub 2022 May 29.
Non-melanoma skin cancer (NMSC) is the most common malignancy worldwide, with rising incidence in the recent years. It includes basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). Several non-invasive therapies have been developed for its treatment such as topical 5-Fluorouracil (5FU) and photodynamic therapy (PDT), among others. Despite both are appropriated for NMSC treatment, recurrence cases have been reported. To prevent this, in this work we explore the potential of the combination of PDT and 5FU to treat SCC and BCC. First we evaluate the efficacy of PDT in cells resistant to 5FU. For this purpose, we use SCC-13 and CSZ-1 cells, obtained from a human SCC and a murine BCC, respectively. We first induced 5FU resistance in these cell lines by repeated treatments with the drug and then, the efficacy to PDT was evaluated. The results obtained indicated that SCC-5FU resistant cells were sensible to PDT administration, whereas BCC-5FU resistant cells were also resistant to PDT. The observed responses in both cell lines are in concordance to Protoporphyrin IX (PpIX) and reactive oxygen species (ROS) levels produced after the incubation with MAL and subsequent light exposure. The obtained data support the fact that PDT seems to be an appropriate therapeutic option to be administered after 5FU resistance in SCC. However, PDT would not be a choice therapy for resistant BCC cells to 5FU.
非黑色素瘤皮肤癌(NMSC)是全球最常见的恶性肿瘤,近年来发病率呈上升趋势。它包括基底细胞癌(BCC)和鳞状细胞癌(SCC)。已经开发出几种非侵入性疗法来治疗这种疾病,例如局部 5-氟尿嘧啶(5FU)和光动力疗法(PDT)等。尽管这两种方法都适用于 NMSC 的治疗,但也有报道称会出现复发病例。为了预防这种情况,我们在这项工作中探索了 PDT 和 5FU 联合治疗 SCC 和 BCC 的潜力。首先,我们评估了 PDT 在对 5FU 耐药的细胞中的疗效。为此,我们使用 SCC-13 和 CSZ-1 细胞,分别来自人 SCC 和鼠 BCC。我们首先通过反复用药物处理来诱导这些细胞系对 5FU 的耐药性,然后评估 PDT 的疗效。结果表明,SCC-5FU 耐药细胞对 PDT 给药敏感,而 BCC-5FU 耐药细胞也对 PDT 耐药。在这两种细胞系中观察到的反应与 MAL 孵育后产生的原卟啉 IX(PpIX)和活性氧(ROS)水平一致。获得的数据支持这样一个事实,即 PDT 似乎是 SCC 中出现 5FU 耐药后进行治疗的合适选择。然而,PDT 不是治疗对 5FU 耐药的 BCC 细胞的选择疗法。